Fig. 3

Anti-HBV treatment with lamivudine reduces cIAP2 expression and partially restores sensitivity to sorafenib in liver cancer cell. a-c HepG2.215 cells were first treated with or without lamivudine, and then further treated with sorafenib. Twenty-four h post sorafenib treatment, a the expression of cIAP2 and cleaved caspase-3 was determined by western blot, b HBV DNA in cultured supernatant was measured by RT-PCR, and c cell viability was assessed by MTT. For western blot, one representative data out of three is shown. For HBV DNA quantification and cell viability, data shown are mean ± SD of three independent experiments. ns, not statistically significant; *, p < 0.05; **, p < 0.01